Ticker Details
Corvus Pharmaceuticals, Inc. Common Stock Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
IPO Date:	March 21, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.06B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.21 | 3.70%
Avg Daily Range (30 D):	$0.54 | 3.63%
Avg Daily Range (90 D):	$0.63 | 4.09%

Institutional Daily Volume
Avg Daily Volume:	.65M
Avg Daily Volume (30 D):	1.44M
Avg Daily Volume (90 D):	2.59M

Trade Size
Avg Trade Size (Sh.):	173
Avg Trade Size (Sh.) (30 D):	76
Avg Trade Size (Sh.) (90 D):	93

Institutional Trades
Total Institutional Trades:	378
Avg Institutional Trade:	$1.86M
Avg Institutional Trade (30 D):	$2.06M
Avg Institutional Trade (90 D):	$2.09M
Avg Institutional Trade Volume:	.19M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.55M
Avg Closing Trade (30 D):	$2.28M
Avg Closing Trade (90 D):	$2.88M
Avg Closing Volume:	233.73K

News

Apr 27, 2026 @ 5:00 PM Peripheral T-Cell Lymphoma Market to Witness Signi... Source: Delveinsight

Feb 2, 2026 @ 5:48 PM Momentum Is Just Starting for These 3 Rapid-Growth... Source: Nathan Reiff

Jan 23, 2026 @ 10:00 PM Corvus Pharmaceuticals Announces Closing of Upsize... Source: Corvus Pharmaceuticals, Inc.

Jan 22, 2026 @ 3:53 AM Corvus Pharmaceuticals Announces Pricing of Upsize... Source: Na

Oct 17, 2025 @ 2:00 PM Corvus Pharmaceuticals Announces Presentation of I... Source: Corvus Pharmaceuticals

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.52	$-.15	$-.15
Diluted EPS	$-.52	$-.15	$-.15
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-44.17M	$-13.69M	$-12.32M
Operating Income / Loss	$-47.93M	$-14.88M	$-12.22M
Cost of Revenue
Net Cash Flow	$35.1M	$35.53M	$1.71M
PE Ratio